Mevion Medical Systems doesn’t have the name recognition of its medical industry peers down I-495 such as Boston Scientific or Hologic, but from its unassuming office, Mevion has made critical connections worldwide with its proton therapy, a type of cancer radiation treatment historically limited to only a few centers.
Led by Tina Yu, Mevion was the first to launch proton therapy in Europe in 2018 with its Dutch offices, and has moved into China, Taiwan and Spain. Today, Mevion has offices in China, and Japan, and has positively impacted the lives of more than 6,000 cancer patients.
Yu has the right background to keep Mevion on its fast trajectory, which expanded its workforce 20% in the last year. She was a senior research scientist before entering health investment and consulting, including co-founding YuanMing Capital, which specializes in investment between the U.S. and China.
What do you think the future holds for Central Mass.? “Massachusetts benefits from the high-tech community, which has helped the state thrive through economic hardships and now public health ones as well. .. I foresee a more robust future as we partner with local health systems and manufacturers to help excel this growth.”
Scientist: Yu has a Ph.D. in chemistry from Princeton.
